Novo Holdings A/S (COAG) discloses 9.0% beneficial stake in Hemab Therapeutics

Rhea-AI Filing Summary

Novo Holdings A/S, a Danish investment firm wholly owned by Novo Nordisk Foundation, reports a significant position in Hemab Therapeutics Holdings, Inc. common stock. Novo Holdings A/S beneficially owns 4,180,550 shares of Hemab’s common stock, representing 9.0% of the outstanding class.

Novo Holdings A/S has sole voting power and sole dispositive power over all 4,180,550 shares and no shared voting or dispositive power. The filing states that, based on the governance structure of Novo Holdings A/S and Novo Nordisk Foundation, the Foundation is not deemed to have beneficial ownership of these securities.

Hemab’s principal executive offices are located in Cambridge, Massachusetts, while Novo Holdings A/S’s principal business office is in Hellerup, Denmark. The certification section is marked not applicable, and the report is signed by Barbara Fiorini, General Counsel, Finance & Operations of Novo Holdings A/S.

Key Figures

Shares beneficially owned: 4,180,550 shares Percent of class: 9.0% Sole voting power: 4,180,550 shares +2 more

5 metrics

Shares beneficially owned 4,180,550 shares Common stock of Hemab Therapeutics beneficially owned by Novo Holdings A/S

Percent of class 9.0% Portion of Hemab Therapeutics common stock class held by Novo Holdings A/S

Sole voting power 4,180,550 shares Shares over which Novo Holdings A/S has sole power to vote

Sole dispositive power 4,180,550 shares Shares over which Novo Holdings A/S has sole power to dispose

Par value per share $0.0001 per share Par value of Hemab Therapeutics common stock

Key Terms

beneficially owned, sole voting power, sole dispositive power, percent of class

4 terms

beneficially owned financial

"Amount beneficially owned: 4,180,550"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole power to vote or to direct the vote: 4,180,550"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 4,180,550"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

percent of class financial

"Percent of class: 9.0%"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

What stake does Novo Holdings A/S report in Hemab Therapeutics (COAG)?

Novo Holdings A/S reports beneficial ownership of 4,180,550 shares of Hemab Therapeutics common stock, representing 9.0% of the outstanding class, according to the Schedule 13G ownership disclosure.

How much voting power does Novo Holdings A/S have in Hemab Therapeutics (COAG)?

Novo Holdings A/S has sole voting power over 4,180,550 shares of Hemab Therapeutics and no shared voting power, giving it independent authority to vote those shares.

Does Novo Nordisk Foundation directly own Hemab Therapeutics (COAG) shares?

The filing states the Novo Nordisk Foundation is not deemed to have beneficial ownership of Hemab Therapeutics securities held by Novo Holdings A/S, based on their governance structure.

What is the class of securities Novo Holdings A/S holds in Hemab Therapeutics (COAG)?

Novo Holdings A/S holds Hemab Therapeutics common stock with a par value of $0.0001 per share, identified under CUSIP number 423494103 in the ownership report.

Where are Hemab Therapeutics and Novo Holdings A/S based?

Hemab Therapeutics’ principal executive offices are at 101 Main Street, Suite 1220, Cambridge, MA 02142, while Novo Holdings A/S’s principal business office is in Hellerup, Denmark.

Who signed the Novo Holdings A/S ownership report for Hemab Therapeutics (COAG)?

The ownership report is signed by Barbara Fiorini, identified as General Counsel, Finance & Operations of Novo Holdings A/S, confirming the information on Hemab Therapeutics share ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:06 PM Accepted by SEC EDGAR 08/14/2026 - 05:05 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Hemab Therapeutics Holdings, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

423494103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Novo Holdings A/S

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DENMARK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,180,550.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,180,550.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,180,550.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Hemab Therapeutics Holdings, Inc.
(b)	Address of issuer's principal executive offices: 101 Main Street, Suite 1220, Cambridge, MA, 02142.
Item 2.
(a)	Name of person filing: Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the "Foundation"), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies, currently comprised of Novo Nordisk A/S and Novonesis A/S, and is responsible for managing the Foundation's assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.
(b)	Address or principal business office or, if none, residence: Tuborg Havnevej 19 2900 Hellerup, Denmark
(c)	Citizenship: Denmark
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 423494103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4,180,550
(b)	Percent of class: 9.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,180,550
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4,180,550
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Novo Holdings A/S

Signature:	Barbara Fiorini
Name/Title:	Barbara Fiorini, General Counsel, Finance & Operations
Date:	08/14/2026